FCGR2B and systemic lupus erythematosus: Clinical studies have observed down-regulation of FcγRIIB on DCs in SLE patients [353] and upregulation of FcγRIIB expression on DCs in RA patients with low disease activity [354], suggestive of a protective role against pathogenic inflammatory responses.